首页> 外文期刊>Journal of cutaneous pathology >Basaloid tumors in nevus sebaceus revisited: The follicular stem cell marker PHLDA1 (TDAG51) indicates that most are basal cell carcinomas and not trichoblastomas
【24h】

Basaloid tumors in nevus sebaceus revisited: The follicular stem cell marker PHLDA1 (TDAG51) indicates that most are basal cell carcinomas and not trichoblastomas

机译:再次探讨皮脂腺痣的基底节肿瘤:滤泡干细胞标记物PHLDA1(TDAG51)表明,大多数是基底细胞癌,而不是成毛细胞瘤

获取原文
获取原文并翻译 | 示例
           

摘要

Background Until the 1990s, basal cell carcinoma (BCC) was viewed as the most common epithelial neoplasm developing in association with nevus sebaceus (NS). Currently, trichoblastoma is thought of as the most prevalent basaloid neoplasm in NS. The follicular stem cell marker pleckstrin homology-like domain, family A, member 1 (PHLDA1) also known as T-cell death-associated gene 51 (TDAG51) labels trichoepithelioma (TE) but not BCC. Therefore, we explored its usefulness in basaloid neoplasms developing in NS. Methods We studied immunohistochemically PHLDA1 in 10 nodular BCCs, 11 TEs, 11 trichoblastomas and 25 NS with basaloid tumors. Additionally, we examined the expression of BCC marker BerEP4 and the distribution of Merkel cells that function as surrogate markers for benign follicular neoplasms. Results Nineteen of the 25 basaloid tumors in NS were PHLDA1-negative comparable to BCC arising de novo and six tumors were PHLDA1-positive comparable to solitary trichoblastomas and TEs. Fewer Merkel cells were seen in BCCs associated with NS when compared with trichoblastoma. BerEP4 did not discriminate between the neoplasms. Conclusions We raise concern that the unquestioned assessment that basaloid tumors developing in association with NS represent mostly trichoblastomas and not BCC may not be true. This influences clinical care, as it is paramount in the decision of whether to excise these lesions or not.
机译:背景技术直到1990年代,基底细胞癌(BCC)被认为是与皮脂痣(NS)联合发展的最常见的上皮肿瘤。目前,毛母细胞瘤被认为是NS中最普遍的基底类赘生物。滤泡干细胞标志物pleckstrin同源样结构域,家族A,成员1(PHLDA1),也称为T细胞死亡相关基因51(TDAG51),标记三叉神经上皮瘤(TE),但不标记BCC。因此,我们探讨了其在NS发生的基底型肿瘤中的有用性。方法我们采用免疫组织化学方法对10例结节性BCC,11例TEs,11例成纤维细胞瘤和25例基底节样肿瘤NS进行了PHLDA1研究。此外,我们检查了BCC标记BerEP4的表达以及作为良性滤泡性肿瘤替代标记的默克尔细胞的分布。结果NS的25例基底类肿瘤中有19例从头产生的BCC与PHLCA1阴性相当,而与单发成纤维细胞瘤和TE相比,有6例PHLDA1阳性。与绒毛母细胞瘤相比,在与NS相关的BCC中发现较少的默克尔细胞。 BerEP4不能区分肿瘤。结论我们引起关注的是,毫无疑问的评估是基底膜肿瘤与NS联合发展主要代表了成纤维细胞瘤而不是BCC,这可能是不正确的。这影响了临床护理,因为在决定是否切除这些病变方面至关重要。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号